A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells.

Cremer, F W; Kiel, K; Sucker, C; Wacker, J; Atzberger, A; Haas, R; Goldschmidt, H; Moos, M

Cremer, F W; Kiel, K; Sucker, C; Wacker, J; Atzberger, A; Haas, R; Goldschmidt, H; Moos, M.

Affiliation

Cremer FW; Department of Internal Medicine V, University of Heidelberg, Germany.

Leukemia ; 11 Suppl 5: S41-6, 1997 Dec.

Article in En | MEDLINE | ID: mdl-9436938

Subject(s)

Antigens, CD34/blood; Hematopoietic Stem Cell Mobilization/methods; Hematopoietic Stem Cells/immunology; Multiple Myeloma/therapy; Adult; Antigens, CD/blood; Base Sequence; DNA Primers; Female; Genes, Immunoglobulin; Hematopoietic Stem Cells/pathology; Humans; Immunoglobulin Heavy Chains/genetics; Leukapheresis/methods; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma/genetics; Multiple Myeloma/immunology; Multiple Myeloma/pathology; Neoplasm Staging; Polymerase Chain Reaction; Receptor-CD3 Complex, Antigen, T-Cell/genetics

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Hematopoietic Stem Cells / Antigens, CD34 / Hematopoietic Stem Cell Mobilization / Multiple Myeloma Type of study: Guideline Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 1997 Type: Article

Search on Google

XML

PubMed Links